Resource use for treatment of childhood & adolescent atopic dermatitis
Research type
Research Study
Full title
A Real World evaluation to describe NHS resource use for the management of moderate to severe atopic dermatitis in secondary care for children and adolescents aged 6 to 17
IRAS ID
252246
Contact name
Jenna Roberts
Contact email
Sponsor organisation
Sanofi
Duration of Study in the UK
0 years, 2 months, 16 days
Research summary
Summay of Research
The study is interested in child and adolescent patients with moderate to severe atopic dermatitis. We want to look at how these patients are currently treated in secondary care and the impact this has on the healthcare system in terms of resource use. For example, what medication they are prescribed, how often they have routine hospital appointments and whether they have had any emergency visits or hospitalizations due to their atopic dermatitis. In order to do this, hospital research staff will be asked to provide patient information taken from patient medical records by entering this into an standardized anonymised form. Patients themselves will not be directly involved in the research but their historic medical record information will be used. It is expected that 4 – 5 UK hospitals will be involved in the study and will provide information on approximately 80 child/adolescent moderate to severe atopic dermatitis patients. Data collection should only last 1 -3 months to allow the research teams enough time to complete the study forms.An understanding of current care for moderate to severe atopic dermatitis patients will allow the impact of new treatments to be assessed. Dupilumab is one such new treatment that is expected to be available from next year. Currently, in the published literature there is minimal information describing UK healthcare resource use for this patient group so it is difficult to assess the impact of dupilumab against current standard of care.
Summary of Results
The study was interested in child and adolescent patients with moderate to severe atopic dermatitis. We wanted to look at how these patients are currently treated in secondary care and the impact this has on the healthcare system in terms of resource use. For example, what medication they are prescribed, how often they have routine hospital appointments and whether they have had any emergency visits or hospitalizations due to their atopic dermatitis. In order to do this, hospital research staff were asked to provide patient information taken from patient medical records by entering this into an standardized anonymised form. Patients themselves were not directly involved in the research but their historic medical record information was used. 4 UK hospitals were involved in the study and provided information on 55 child/adolescent moderate to severe atopic dermatitis patients.
An understanding of current care for moderate to severe atopic dermatitis patients allowed the impact of new treatments to be assessed.
In the published literature there was minimal information describing UK healthcare resource use for this patient group so it was difficult to assess the impact of new potential drugs against current standard of care. The study revealed a high level of clinical tests, multiple per-patient treatment prescriptions, and a high frequency of consultations among child & adolescent AD patients, with a large negative impact on QoL indicated by PROs. These findings demonstrate that there is high resource use, and poor QoL among these patients with moderate to severe AD, suggesting novel therapies are required.REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
18/SW/0295
Date of REC Opinion
22 Jan 2019
REC opinion
Further Information Favourable Opinion